VINBLASTINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Vinblastine, and when can generic versions of Vinblastine launch?
Vinblastine is a drug marketed by Abraxis Pharm, Fresenius Kabi Usa, Hikma, and Hospira. and is included in four NDAs.
The generic ingredient in VINBLASTINE is vinblastine sulfate. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the vinblastine sulfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Vinblastine
A generic version of VINBLASTINE was approved as vinblastine sulfate by HIKMA on April 9th, 1987.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for VINBLASTINE?
- What are the global sales for VINBLASTINE?
- What is Average Wholesale Price for VINBLASTINE?
Summary for VINBLASTINE
| US Patents: | 0 |
| Applicants: | 4 |
| NDAs: | 4 |
| Drug Prices: | Drug price information for VINBLASTINE |
| DailyMed Link: | VINBLASTINE at DailyMed |
US Patents and Regulatory Information for VINBLASTINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | VINBLASTINE SULFATE | vinblastine sulfate | INJECTABLE;INJECTION | 089011-001 | Nov 18, 1985 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hospira | VINBLASTINE SULFATE | vinblastine sulfate | INJECTABLE;INJECTION | 089565-001 | Aug 18, 1987 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Fresenius Kabi Usa | VINBLASTINE SULFATE | vinblastine sulfate | INJECTABLE;INJECTION | 089515-001 | Apr 29, 1987 | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
